AMENDMENTS TO THE CLAIMS

Please amend the claims as follows. This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently amended) A method for manufacturing a medicament for the treatment of a ~~patient suffering from~~ a disease or a disorder correlated directly or indirectly with sarcoidosis, comprising providing ~~administering to the patient~~ a peptide or a polypeptide comprising the following amino acid sequence:

Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu (SEQ ID No.4); and
a pharmaceutically acceptable carrier.

2. (Previously Presented) The method according to claim 1, wherein said peptide or said polypeptide further comprises at least one of the following amino acid sequences:

His-Ser-Asp (SEQ ID No. 14); and Phe-Thr-Asp (SEQ ID No. 13).

3. (Previously Presented) The method according to claim 1, wherein said peptide or said polypeptide further comprises the amino acid sequences His-Ser-Asp (SEQ ID No. 14) and Phe-Thr-Asp (SEQ ID No. 13).

4. (Previously Presented) The method according to claim 1, wherein said peptide or said polypeptide has the following amino acid sequence:

$(A)_n$-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-$(B)_m$ (SEQ ID No. 15)
wherein
$(A)_n$ and $(B)_m$ vary independently and are amino acid sequences comprising any sequence of naturally occurring amino acids;
wherein n is an integer ranging from 0 to 25 and n is the number of amino acid residues in said amino acid sequence $(A)_n$; and
wherein m is an integer ranging from 0 to 25 and m is the number of amino acid residues in said amino acid sequence $(B)_m$.

5. (Previously Presented) The method according to claim 4, wherein, if $n > 2$, $(A)_n$ further comprises a primary amino acid sequence:
$(X)_o$ -Phe-Thr-Asp-$(Y)_p$

wherein $(X)_o$ and $(Y)_p$ vary independently and are primary amino acid sequences comprising any sequence of naturally occurring amino acids; and wherein o is an integer ranging from 0 to 11 representing the number of amino acid residues in said amino acid sequence $(X)_o$; and wherein p is an integer ranging from 0 to 11 representing the number of amino acid residues in said amino acid sequence $(Y)_p$.

6. (Previously Presented) The method according to claim 5, wherein, if o > 2, $(X)_o$ has the following sequence:
$(X')_q$-His-Ser-Asp-$(X'')_r$

wherein X', X" is $(X')_q$ and $(X'')_r$ vary independently and are amino acid sequences comprising any sequence of natural occurring amino acids; wherein q is an integer ranging from 0 to 4 representing the number of amino acid residues in said amino acid sequence $(X')_q$; and wherein r is an integer ranging from 0 to 4 representing the number of amino acid residues in said amino acid sequence $(X'')_r$.

7. (Previously Presented) The method according to claim 4, wherein the sequence of said peptide or said polypeptide is selected from the following group:

(i) Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu (SEQ ID No. 4);

(ii) Phe-Thr-Asp-X^1-X^2-X^3-X^4-X^5 -Arg-Lys-Gln-Met-Ala-Val-Lys Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn (SEQ ID No.5);

(iii) Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn (SEQ ID No. 6);

(iv) Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu (SEQ ID No. 7);

(v) His-Ser-Asp-X^1-X^2-Phe-Thr-Asp -X^3-X^4-X^5-X^6-X^7-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu (SEQ ID No.8);

(vi) His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu (SEQ ID No. 9);

(vii) His-Ser-Asp-Gly-Ile-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg
Lys-Gln-Met-Ala-VaI-Lys-Lys-Tyr-Leu (SEQ ID No. 10);

(viii) His-Ser-Asp-X^1-X^2-Phe-Thr-Asp -X^3-X^4-X^5-X^6-X^7-Arg-Lys-
Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-X^8-X^9-X^{10}-X^{11}(-X^{12}) (SEQ ID No. 11);

(ix) His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-
Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn (SEQ ID No. 1, VIP);

(x) His-Ser-Asp-Gly-Ile-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-
Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Ala-Ala-Val-Leu (SEQ ID No. 3, PACAP-27);

(xi) His-Ser-Asp-X^1-X^2-Phe-Thr-Asp-X^3-X^4-X^5-X^6-X^7-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-
Leu-X^8-X^9-X^{10}-X^{11}-X^{12}-X^{13}-X^{14}-X^{15}-X^{16}-X^{17}-X^{18}-X^{19}-X^{20}-X^{21}-X^{22} (SEQ ID No. 12); and

(xii) His-Ser-Asp-Gly-Ile-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-Met-Ala-Val-Lys-
Lys-Tyr-Leu-Ala-Ala-Val-Leu-Gly-Lys-Arg-Tyr-Lys-Gln-Arg-Val-Lys-Asn-Lys (SEQ ID No.2, PACAP-38);
wherein X^1 – X^{22} is any naturally occurring amino acid residue.

8. (Previously Presented) The method according to claim 7, wherein any of said peptides or polypeptides is in a stabilized form.

9. (Currently Amended) The method according to ~~any of the claims 1 - 8~~ claim 8, wherein said peptide or said polypeptide has the biological function of, or is functionally similar to VIP or PACAP, or any biologically active derivative, truncated form, analogue or fusion protein thereof.

10. (Previously Presented) The method according to ~~any of the claims 1 – 8~~ claim 8, wherein said peptide or said polypeptide is provided as an aerosol applicable for inhalation.